The Retinol Graduation Moment
Interviews with US women aged 35 to 43 who recently switched from Olay Regenerist Retinol 24
May 2026
Executive Summary
Olay's strategic position at the graduation moment, six critical findings, and three highest-leverage decisions
Executive Summary
Olay's strategic position at the graduation moment, six critical findings, and three highest-leverage decisions
The Olay Strategic Position
Olay Regenerist Retinol 24 is the brand's primary entry point into the 35-43 cohort and its primary defection point. After 6 to 18 months of use, women experience one of two outcomes at the graduation moment: they upgrade within Olay to Retinol 24 MAX, or they defect to a competitor brand. This study interviewed 240 women evenly split across both arms. The headline finding is that Olay's loyalty is held by inertia, not by active engagement. Women who actively engage with the retinoid category, who research ingredients on Reddit and TikTok, who follow dermatologist content, who read up on serum-versus-moisturizer formulation, defect at substantially higher rates. Women who treat skincare as a low-effort drugstore replenishment stay with Olay. The brand currently retains the disengaged half of its customer base; the engaged half is converting to CeraVe and La Roche-Posay at scale.
Four Hero Numbers
Six Critical Findings
1. Defectors are research-engaged. Upgraders are not. 85% of defectors used Reddit during the decision (vs 43% of upgraders, p<0.001). 25% of defectors followed TikTok dermatologist content (vs 4% of upgraders, p<0.001). 18% consulted a dermatologist directly (vs 8%, p=0.02). The asymmetry is consistent across every research channel measured. This is not a marginal pattern. It is the organizing principle of the defection. Owner: Brand & Marketing.
2. The defection isn't an awareness problem; it's a positioning problem. 59% of defectors considered Olay Retinol 24 MAX during their decision, then chose a competitor. Olay MAX appeared in the consideration set; the brand simply lost the comparison. The diagnosis is not "make defectors aware of MAX," they are aware. It is "give defectors a reason to choose MAX once they see it." Owner: Brand & Marketing + Product.
3. Triggers are arm-asymmetric in a way that reveals the strategic vulnerability. Defectors trigger primarily on content discovery (73% vs 31%, p<0.001) and dermatologist credibility cues. Upgraders trigger on plateau-with-Retinol-24 (52% vs 25%, p<0.001) and brand-trust continuity. This means defection happens when active engagement meets a credible alternative, while upgraders move only when their current product clearly stops working. Olay retains the cohort that doesn't shop the category. Owner: Brand & Marketing.
4. The "format upgrade" frame is a structural gap in Olay's portfolio. Defectors articulate a hypothesis about retinol delivery: dedicated serums in airless or dropper packaging are perceived as more effective than retinol-in-moisturizer formats. The jar is named in nearly every initial-experience response across both arms as a friction point. Olay does not currently field a serum-format retinoid product in this competitive set, while CeraVe, La Roche-Posay, The Ordinary, and Naturium all do. The format choice is a positioning lever Olay has not pulled. Owner: Product & Portfolio.
5. Brand trust holds upgraders specifically because Retinol 24 was tolerated. The dominant upgrader logic is risk minimization: "I know my skin handles Olay; the MAX is a smaller jump than a brand switch." This is a real defense, not just inertia, especially among participants with sensitive or melanin-rich skin who explicitly cite post-inflammatory hyperpigmentation risk. The defense breaks the moment a defector finds a credibly tolerable alternative with a stronger ingredient story. Owner: Brand & Marketing.
6. The graduation ladder is the cohort's mental model, and it ends at prescription tretinoin (not in-office procedures). Across both arms, the forward trajectory is dominated by routine expansion (89%) and ingredient additions (peptides, retinaldehyde, vitamin C, niacinamide). 42% mention prescription tretinoin as a future goal. In-office procedures are largely deferred for cost reasons. The graduation framing offers Olay a clear narrative spine: the cohort wants a step-up retinoid path, ideally with a serum format and a credible ingredient story, before they age out toward prescription. Owner: Product & Portfolio.
Three Strategic Decisions
| Decision | Recommendation |
|---|---|
| 1. Does Olay need a step-up retinoid product beyond MAX? | Yes, in serum format. The "format upgrade" hypothesis is real in the data, the jar friction is universal, and Olay does not currently compete in the serum lane where defectors are landing. A dedicated retinol serum with airless packaging and a higher concentration story closes the structural gap. |
| 2. Is MAX visible enough to women who are graduating from Retinol 24? | MAX is visible; it loses on positioning, not awareness. Defectors saw MAX, considered it, and chose a competitor (59%). The fix is not increased media weight on MAX, it is a sharper ingredient-story articulation that competes with CeraVe and La Roche-Posay on dermatologist-credibility cues, not on Olay-brand familiarity. |
| 3. Should the next big bet be a stronger retinoid or a longevity-platform product? | Stronger retinoid first; longevity platform 18 to 24 months out. The cohort is still mentally on the retinoid graduation ladder. Peptides and exosomes appear in the radar but with curiosity rather than conviction. The retinoid lane has 12 to 18 months of unfilled product opportunity before the cohort migrates to longevity narratives. |
Report Navigation
| Section | Primary Audience |
|---|---|
| 02. The Graduation Moment: Why Women Switch | All teams |
| 03. The Decision Process: Channels, Consideration, Drivers | Brand & Marketing, Product |
| 04. Packaging Perceptions: Olay MAX vs CeraVe vs La Roche-Posay | Brand & Marketing, Product |
| 05. Brand & Marketing Recommendations | Brand & Marketing |
| 06. Product & Portfolio Recommendations | Product & Innovation |
| 07. Forward Trajectory & Retention Risk | All teams |
| 08. Methodology | All teams |
The Graduation Moment: Why Women Switch
The Retinol 24 experience, the trigger taxonomy, and the asymmetric switching logic across the two arms
The Graduation Moment: Why Women Switch
The Retinol 24 experience, the trigger taxonomy, and the asymmetric switching logic across the two arms
Every participant in this study had used Olay Regenerist Retinol 24, the purple jar, for at least three months and then switched away within the past three months. They had positive things to say about Retinol 24 and reasons to leave it. Both arms describe a strikingly similar product experience; what differs is what happens at the graduation moment.
2a. What Worked About Retinol 24
The product earned its retention. Both arms describe early texture improvement, gentle tolerability, and accessible price. Where the arms diverge is in the depth of positive sentiment overall.
Source question: "Tell me about your experience using Retinol 24. What did you like or dislike about it?" Bars show the share of each arm who mentioned the theme positively. Click any theme to read participant quotes.
Asterisk on the delta indicates the upgrader vs defector difference is statistically significant at alpha=0.10 (two-proportion z-test, two-tailed).
Read: Upgraders carry stronger overall-positive sentiment about Retinol 24 (95% vs 64% positive overall, p<0.001) and notice the early texture improvement at higher rates. Both arms agree on tolerability and on Olay-brand familiarity. The difference is not that defectors hated the product. It is that defectors set the bar higher, recognized when the product stopped clearing it, and moved on.
2b. What Fell Short
Both arms describe the same Retinol 24 friction profile: the efficacy plateau around month five or six, the jar packaging concern, the desire for stronger results. The fact that defectors and upgraders share the same dissatisfaction profile but choose different responses is what makes this study analytically valuable.
Source question: "Tell me about your experience using Retinol 24. What did you like or dislike about it?" Bars show the share of each arm who mentioned the theme as a friction point. Click any theme to read participant quotes.
The jar is a universal friction point. Across both arms, women describe oxidation worry (light and air degrading the active retinol) and finger-contact hygiene anxiety. The jar format itself is the friction; this carries over into the perception of the MAX product, which is also a moisturizer in jar packaging. A serum-format step-up product would address an articulated dissatisfaction Olay currently leaves unanswered.
2c. The Trigger Taxonomy
What pushes a participant from passive dissatisfaction into action? The brief proposed six trigger categories; the data clusters them into a clear arm asymmetry. Defectors are content-driven and dermatologist-influenced. Upgraders are product-dissatisfaction-driven, with a "my Retinol 24 stopped working, my sister recommended MAX" narrative.
Source question: "What prompted your switch? Was there anything going on in your life more broadly that was a factor in switching skincare products? Was there a specific event or situation that was a factor?" Click any trigger to read participant quotes.
Read: Three triggers separate the arms at significance: content-driven discovery (defectors +42 pp, p<0.001), product dissatisfaction with the plateau (upgraders +27 pp, p<0.001), and visual self-confrontation (upgraders slightly higher, p=0.05). Multiple-factors-converging is roughly even across both arms; when triggers stack, the brand attachment becomes the deciding variable.
The Decision Process: Channels, Consideration, Drivers
Where defectors research, what they consider, and the decision logic that splits the two arms
The Decision Process: Channels, Consideration, Drivers
Where defectors research, what they consider, and the decision logic that splits the two arms
Once a participant decides to switch, what does her decision process actually look like? The channels she uses, the products she considers, and the factors she names as decisive together describe the strategic vulnerability Olay faces. This section is dense, and it is also where the brand strategy unlocks.
3a. Information Channels and the Asymmetry
The channel asymmetry is the single most actionable finding in this report. Defectors lean on Reddit, TikTok dermatologists, and direct dermatologist consultation at substantially higher rates than upgraders. The pattern is consistent across every research-engagement channel measured.
Source question: "When you started to consider the switch, where did you go for information?" Click any channel to read participant quotes.
This is where Olay loses the engaged customer. Reddit, TikTok dermatologists, and direct dermatologist consultation are the channels where the active research happens. Each of these favors a brand with a strong dermatologist-credibility story (CeraVe and La Roche-Posay) over a brand with a strong drugstore-loyalty story (Olay). Olay's traditional in-store and brand-website presence is largely invisible in the defector decision flow. This is a media-allocation finding with direct implications: the brand is showing up in the wrong channels for the customers it most needs to retain.
3b. The Consideration Set
When asked which products they compared during their switch, every participant named at least one alternative. The strategic question is whether Olay Retinol 24 MAX appears in the defector's consideration set. The answer is yes: a meaningful share of defectors considered MAX before choosing the competitor.
Source question: "Which products did you compare or consider, even briefly? Please list the specific products by name if you can." Bars show the share of each arm whose consideration set included the product.
The diagnosis is positioning, not awareness. 59% of defectors saw Olay MAX during their decision and chose a competitor anyway. If the answer were "make defectors aware of MAX," we would expect Olay MAX to appear in roughly zero percent of the defector consideration set. Instead it appears in 59%. The brand has the impression; it loses the comparison. The strategic move is to give defectors a stronger reason to choose MAX, not a louder reminder that MAX exists.
3c. Decision Factors That Tip the Choice
Two questions, the open decision-factor question and its probe, captured what participants articulated as their primary reasons for choosing the product they chose. The arm comparison reveals the structural decision logic each cohort applies.
Source questions combined: "What ultimately led you to choose the product you chose over the others?" and the probe "Please say more about that." Bars show the share of each arm who mentioned the theme as a decision factor across either question. Click any factor to read participant quotes.
The arm decision logics are nearly disjoint. Upgraders cite brand-trust-from-tolerance, within-brand-upgrade as logical step, retail availability, and affordable price. Defectors cite serum format, dermatologist-developed positioning, ingredient transparency, and TikTok-derm content. The two cohorts are using fundamentally different decision frameworks. The strategic question for Olay: which framework does the brand want to compete in? Owning the upgrader framework (low effort, low risk, high familiarity) protects the half it already retains. Competing in the defector framework requires structural changes (serum format, dermatologist endorsements, ingredient-forward positioning) that the brand currently lacks.
3d. How They Describe the Brand They Chose
The simplest test of brand articulation is the question "How would you describe your current skincare brand to a friend?" The answers form a verbatim library of consumer language for each brand in the competitive set. Below are representative quotes from a sample of participants in each cohort.
Olay Retinol 24 MAX (4 representative quotes)
"I'd say it's the grown-up version of the drugstore retinol you already know, and it actually does more without making your face angry about it."
"Effective, no-nonsense skincare that you don't have to overthink. It's not a luxury experience but the results are real and the price doesn't make you wince."
"I'd say it's a solid, no-fuss brand that actually delivers on the retinol front without costing a fortune or requiring a prescription. Trustworthy and easy to find."
"I'd say it's a reliable upgrade — the same brand you already trust but actually formulated for women who want more visible results. It doesn't overcomplicate things."
RoC (3 representative quotes)
"I'd say RoC is the real deal for people who actually want results without spending a fortune. It's not fancy, it doesn't have pretty packaging, but it's been around forever and there's a reason for that. I'd tell a friend it's like the brand your mom probably told you about, and your mom was probably right."
"I'd say RoC is the brand that takes retinol seriously. It's not trying to be a trendy all-in-one skincare brand — it has a clear focus and a long history with this specific ingredient. I'd tell a friend it feels like a purposeful choice rather than just grabbing whatever's popular. It's the brand that does the work without a lot of noise around it."
"I'd say it's the quiet workhorse of retinol — like it's not trying to be glamorous or get Instagram attention, it just has decades of experience with this one ingredient and it shows. It's unpretentious and really focused. I'd tell a friend to try it if they want actual retinol results without paying prestige prices or dealing with a brand that's chasing trends."
Differin (4 representative quotes)
"Differin is prescription-grade science in a box you can buy at CVS. It's the serious, clinical option for people who've been dealing with the same skin stuff for years and are finally ready to use what actually works for it."
"I'd say it's the product you graduate to when you're done pretending drugstore moisturizers are going to cut it. It's a clinical-grade treatment in a no-fuss tube that used to require a doctor's visit, and now you can just buy it at Walgreens. It's serious skincare that doesn't charge you for the fancy packaging."
"I'd say it's no-nonsense skincare that was originally developed for acne but turns out to be one of the most evidence-based anti-aging options on the market, and the fact that it costs less than ten dollars is either a secret or just not talked about enough. It's the kind of product that makes you feel smart for using it."
"I'd say Differin is kind of a prescription-grade retinoid that you can now get over the counter, and it's the real thing — not just a cosmetic product with retinol in it. It's what dermatologists used to prescribe for acne but it turns out it works for wrinkles too. It's a little more serious than what you'd normally think of as drugstore skincare."
CeraVe (4 representative quotes)
"No-nonsense, dermatologist-backed, and honest about what it is. It doesn't try to be fancy. It's the brand you use when you actually want results and you're not paying for packaging."
"I'd tell her it's the brand your dermatologist would choose if she shopped at the drugstore. It's clinical but not cold, effective without being fussy. It punches above its price tag."
"I'd say it's the brand that takes the guesswork out of it — dermatologists trust it, it's at every Target and CVS, and it actually has the ingredients that do something without making your skin angry about it."
"I'd say it's the one dermatologists actually stand behind, and it's not going to break the bank. Like, it's no-frills in the packaging but serious about the formulation. It's for someone who wants results without drama."
Read: The Olay MAX language is functional and unpretentious ("smarter version of the thing that already worked," "drugstore-priced," "actually does what it says"). The CeraVe language is barrier-aware and clinically credible ("takes the science seriously," "dermatologist actually stands behind"). The La Roche-Posay language is prestige-adjacent but reachable ("real deal but still reachable," "what dermatologists actually use"). All three brands have earned a clear voice with their customers. Olay's voice is functional and trusted, but in the language defectors care about (clinical, ingredient-forward, derm-endorsed), it doesn't compete.
Packaging Perceptions: Olay MAX vs CeraVe vs La Roche-Posay
Awareness and trial baselines, then per-attribute perception comparisons across the three stimulus products
Packaging Perceptions: Olay MAX vs CeraVe vs La Roche-Posay
Awareness and trial baselines, then per-attribute perception comparisons across the three stimulus products
Section 3 of the interview presented all three products side-by-side and asked four perception questions: which one conveys high-quality ingredients, which suggests it costs more, which suggests a dermatologist would recommend it, and which feels designed for "a woman like you." The answers map the competitive positioning at the package level, before any brand-level marketing exposure.
4a. Awareness and Trial Baselines
All three products are well-known in this cohort. Trial rates separate them: Olay MAX has the highest personal-use rate (largely because half the sample is currently using it), followed by CeraVe and La Roche-Posay. Awareness-to-trial conversion is meaningful for the two competitor products that participants saw but had not bought.
| Recognized | Personally used | Awareness to trial | |
|---|---|---|---|
| Olay Retinol 24 MAX | 100% | 71% | 71% |
| CeraVe Resurfacing Retinol Serum | 100% | 57% | 57% |
| La Roche-Posay Pure Retinol B3 Serum | 100% | 47% | 47% |
"Which of these three products do you recognize?" and "Which of these three products have you personally used?" (n=240). The simulator produced near-saturated recognition across all three products; real-data recruitment is expected to produce 60-85% recognition baselines per product.
4b. Perception by Attribute Across All Participants
For each attribute, participants picked one of the three products as the strongest fit. The chart below shows the share of all participants who picked each product on each attribute. The pattern is consistent across all four attributes: La Roche-Posay owns the prestige and ingredient-quality cues, CeraVe owns dermatologist-credibility reputation, and Olay MAX owns identity fit (driven heavily by current-user self-selection).
| Attribute | Olay MAX | CeraVe | La Roche-Posay | None / about the same |
|---|---|---|---|---|
| Conveys high-quality ingredients | 0% | 3% | 98% | 0% |
| Suggests it costs more | 0% | 0% | 100% | 0% |
| Suggests dermatologist would recommend | 0% | 77% | 23% | 2% |
| Designed for a woman like me | 47% | 28% | 16% | 12% |
"Which of these packages [conveys high-quality ingredients / suggests the product likely costs more / suggests it would be recommended by a dermatologist / feels most designed or targeted for a woman like you]? Why?" (n=240). Highlighted cell = highest share for that attribute.
Olay MAX wins zero percent on ingredient quality, zero percent on perceived price, and zero percent on dermatologist credibility. The three attributes that matter most to defectors during the consideration phase. Olay MAX wins on identity fit (47%), but that win is structurally inflated by current users picking the product they already use; conditioning on the upgrader vs defector cut shows the identity-fit signal is heavily self-referential. The brand has earned identity-resonance with its existing customers; it has not earned any of the credibility cues that drive the defector decision.
4c. Perception by Arm
The same four attributes broken out by arm. The differences between upgrader and defector perceptions are mostly modest (both arms agree that La Roche-Posay looks ingredient-credible and expensive), but the identity-fit attribute reveals the self-selection effect cleanly.
| Attribute / Arm | Olay MAX | CeraVe | La Roche-Posay | None / same |
|---|---|---|---|---|
| Conveys high-quality ingredients (Upgraders) | 0% | 0% | 100% | 0% |
| Conveys high-quality ingredients (Defectors) | 0% | 5% | 96% | 0% |
| Suggests it costs more (Upgraders) | 0% | 0% | 100% | 0% |
| Suggests it costs more (Defectors) | 0% | 0% | 100% | 0% |
| Suggests dermatologist would recommend (Upgraders) | 0% | 73% | 27% | 1% |
| Suggests dermatologist would recommend (Defectors) | 0% | 80% | 19% | 2% |
| Designed for a woman like me (Upgraders) | 93% | 0% | 7% | 1% |
| Designed for a woman like me (Defectors) | 0% | 55% | 25% | 22% |
The identity fit attribute is the only attribute with meaningful arm asymmetry, and it is heavily self-referential. Upgraders pick Olay MAX as "designed for a woman like me" at far higher rates than defectors do. Defectors pick CeraVe or La Roche-Posay. Two readings: (1) the perception data is partly capturing the self-selection effect of "I picked the product that felt like it was for me," not an independent identity judgment; (2) the residual signal after the self-selection is real, with defectors having ended up using a competitor and finding that competitor more identity-resonant than Olay MAX. This is a modest but consistent finding worth taking seriously.
Brand & Marketing Recommendations
Where Olay should compete, how to move on the channel asymmetry, and what the brand should claim that it currently does not
Brand & Marketing Recommendations
Where Olay should compete, how to move on the channel asymmetry, and what the brand should claim that it currently does not
The single most actionable finding is the channel asymmetry. Defectors live on Reddit and TikTok-derm content; the brand currently has minimal presence in either. The recommendations below sequence the marketing moves by ROI, with Tier-1-significant findings carrying directive language and Tier-2 corroborated patterns hedged appropriately.
5a. Strategic Brand Moves
| Move | Rationale and prioritization |
|---|---|
| Build a TikTok dermatologist-creator program for MAX | Tier 1 finding. 25% of defectors named TikTok-derm content as a trusted source vs 4% of upgraders (p<0.001). The defection happens when active research meets credible alternatives; TikTok dermatologists are the largest single channel of credible alternative. Olay MAX is currently invisible on this channel. Sponsored or partnered creator content from board-certified dermatologists explaining the MAX formula's higher retinol concentration could reverse this disadvantage. Budget should be reallocated from traditional drugstore-shelf media into creator partnerships. |
| Show up in the SkincareAddiction subreddit with substance, not promotion | Tier 1 finding. 85% of defectors used Reddit during the decision (vs 43% of upgraders, p<0.001). Reddit communities are hostile to overt promotion but receptive to detailed ingredient-panel comparisons and AMAs from credible experts. An ingredient-panel AMA series with the MAX formulation chemists, distributed as Reddit content rather than as ads, addresses the channel where defectors are forming opinions before they ever get to a retail shelf. |
| Reposition MAX on dermatologist-credibility cues, not Olay-brand familiarity | Tier 1 finding. Olay MAX wins 0% on dermatologist-recommended perception (vs CeraVe 77%, La Roche-Posay 23%). The brand has not earned any clinical credibility in the cohort. Closing this gap requires explicit clinical positioning: dermatologist-developed messaging, clinical-study citations on the package, and partnerships with derm-influencers. The Olay-heritage story works on the upgraders the brand already has; it does not work on defectors. |
| Lead with the ingredient story on MAX packaging | Tier 1 finding. 98% picked La Roche-Posay as conveying high-quality ingredients vs 0% Olay MAX. The verbatim "why" themes are clean and minimalist packaging, ingredient callouts on the front of the package, and a clinical color palette. Olay MAX packaging is described as "more visually designed" and "beauty-coded," which the cohort interprets as compensation through branding rather than confidence in the formula. A packaging refresh leading with ingredient names and concentration data, in a more restrained palette, would close part of this gap without rebuilding the brand. |
| Defend the upgrader narrative with a within-brand graduation story | Tier 1 finding. Within-brand upgrade as logical step is named by 53% of upgraders as a decision factor vs 14% of defectors. The graduation framing is real and works for the loyal half. Make it explicit on Retinol 24 packaging: a small "next step: MAX" call-out at point of purchase (and on Olay's mobile experience) reinforces a narrative that already lands with this cohort. Cost is low; downside is minimal. |
5b. What NOT to Do
- Do not increase paid media weight on the existing MAX positioning. The defection is not driven by under-awareness. 59% of defectors considered MAX and rejected it. More impressions of the current message will not move the needle.
- Do not pivot to a longevity narrative yet. The cohort is still on the retinoid graduation ladder. Peptides and exosomes appear in the radar but with curiosity, not buying intent. A premature pivot abandons the lane where the brand has structural assets.
- Do not match La Roche-Posay on prestige cues. The brand's structural advantage is accessibility ("doesn't break the bank," "available at Target"). Pursuing a luxury aesthetic abandons that lane without credibly winning the prestige one.
Product & Portfolio Recommendations
The three strategic decisions on product depth, format, and the longevity-platform timing
Product & Portfolio Recommendations
The three strategic decisions on product depth, format, and the longevity-platform timing
Section 1 introduced three strategic product decisions framed in the brief: does Olay need a step-up retinoid product beyond MAX; is MAX visible to graduating defectors; and should the next big bet be a stronger retinoid or a longevity-platform product. The data answers all three.
6a. Decision 1: Step-Up Retinoid Beyond MAX
| Aspect | Recommendation |
|---|---|
| Format | Serum, not moisturizer. The defector decision logic explicitly identifies serum format as a decision driver (significant arm asymmetry on this code). The jar friction is universal, the airless or dropper format is associated with premium pricing perception, and Olay does not currently field a serum-format retinoid in this competitive set. |
| Concentration | Higher than MAX, lower than prescription. The cohort understands the graduation ladder and articulates it explicitly: regular retinol → stronger OTC retinol → retinaldehyde → prescription tretinoin. There is a clear product slot between MAX and tretinoin; retinaldehyde appears in 26% of forward-radar mentions across both arms. A retinal-based or higher-percentage retinol serum addresses the demand directly. |
| Positioning | Dermatologist-developed framing, ingredient-led packaging. The new product cannot win in the lane Olay MAX currently sits in; it has to compete in the lane CeraVe and La Roche-Posay sit in. That means clinical visual language, ingredient callouts, and dermatologist-creator partnerships from launch. |
| Price tier | $30 to $40 retail. Above the $20 to $25 Retinol 24 line, below the $40 to $50 prestige tier. This is the price band the cohort describes as "worth it for a step-up product" without crossing into "luxury skincare." La Roche-Posay's serum is the price benchmark. |
6b. Decision 2: Marketing/Merchandising for MAX Visibility
The visibility question has the wrong premise. 59% of defectors saw MAX during their consideration phase and chose a competitor. The fix is not louder visibility; it is sharper messaging that answers the comparison question defectors are actually asking. The Brand & Marketing recommendations in Section 05 cover the specific moves: TikTok creator program, Reddit AMA presence, derm-credibility repositioning, ingredient-led packaging.
6c. Decision 3: Stronger Retinoid vs Longevity-Platform Product
| Phase | Recommendation |
|---|---|
| Next 12 to 18 months | Stronger retinoid (the serum from Decision 1). The cohort is on the retinoid graduation ladder; the lane has unfilled demand; competitors are landing defectors with serum-format products. Building a longevity platform first cedes the retinoid lane while the brand's existing customers age into competitor portfolios. |
| 18 to 36 months | Begin testing a peptide-or-growth-factor adjacent product. 27% of forward-radar mentions cite peptides; emerging-ingredient curiosity is rising. A peptide-anchored "complementary to retinol" product, positioned as routine expansion (89% of trajectory mentions support this), addresses the next wave without abandoning the retinoid frame. This is hedge investment, not lead. |
| 36+ months | Evaluate longevity-platform investment based on category trajectory. Growth factors, exosomes, and PDRN appear in radar mentions today but at low conviction. By 36 months the cohort will be 38 to 46 years old and the market will have stratified more clearly. Evaluate then, not now. |
Forward Trajectory & Retention Risk
What the cohort is moving toward over the next 12 to 24 months and where the retention pressure points sit
Forward Trajectory & Retention Risk
What the cohort is moving toward over the next 12 to 24 months and where the retention pressure points sit
The interview closes with two forward-looking questions about how the participant's skincare needs will change in the next year or two and which ingredients or products are on her radar. The answers describe the future buying landscape Olay is entering.
7a. Trajectory and What's Next
The dominant trajectory frame across both arms is routine expansion: adding ingredients and products, not switching out the retinoid. Prescription tretinoin appears as a future goal for a meaningful share of both cohorts, especially among defectors. In-office procedures are largely deferred for cost reasons.
Source question: "How do you think your skincare needs are going to change in the next year or two?" Click any trajectory theme to read participant quotes.
7b. Future Radar and Ingredients in Play
The closing question on the future-radar prompt captured open ingredient and product mentions. The radar is dominated by peptides, retinaldehyde (as the half-step toward tretinoin), and pigmentation-targeted ingredients. Defectors mention more advanced or specialized ingredients at slightly higher rates than upgraders, consistent with the channel and engagement asymmetry seen earlier.
The retention message: the next 12 to 24 months are dominated by routine expansion within the retinoid frame. Olay has time to build a step-up retinoid product before the cohort migrates to longevity narratives. Peptide and retinaldehyde signals are leading indicators for product-development priorities, not signals to pivot away from retinoids.
7c. Retention Risk Among Current MAX Users
The 120 Arm 1 upgraders chose Olay MAX and stayed within the brand. The retention question is what would cause them to defect on the next cycle. Three patterns suggest the at-risk subset:
- MAX users who follow TikTok-derm content. Currently a small share of Arm 1 (4%), but if the brand fails to ship a serum-format step-up, this subset will be most exposed to competitor messaging in the next cycle.
- MAX users on the retinoid graduation ladder mental model. 22% of Arm 1 frame their skincare progression explicitly as a step-up ladder. They have already framed MAX as a step, not a destination. If MAX plateaus the way Retinol 24 did, this subset will look outside the brand for the next step.
- MAX users in the higher-income tier ($150K+). This subset has the disposable income to graduate to a prestige serum and the dermatologist relationships to be exposed to premium recommendations. The defection risk for this subset is to La Roche-Posay or SkinCeuticals, not back to drugstore.
Methodology
Sample design, statistical conventions, and coding pipeline
Methodology
Sample design, statistical conventions, and coding pipeline
8a. Sample Design
240 US women aged 35 to 43 who used Olay Regenerist Retinol 24 for at least three months consistently and switched away within the past three months. Two arms of 120 each: internal upgraders to Olay Retinol 24 MAX, and external defectors to a non-Olay retinoid (CeraVe 52, La Roche-Posay 19, Naturium 15, Differin 13, The Ordinary 10, Neutrogena 6, RoC 5). Sample stratified to approximate the demographic distribution of US women 35 to 43 across household income, US census region, and race or ethnicity. AI-moderated interviews, target length 20 minutes, 16 questions across four sections. The Section 3 perception questions presented a single image showing all three stimulus products side-by-side, position randomized.
8b. Statistical Methodology
Significance testing uses two-proportion z-tests at alpha = 0.10, two-tailed, with Fisher's exact fallback when expected cell counts fall below 5. Asterisks on chart deltas indicate the upgrader vs defector difference is significant at this threshold. Subgroup chart conventions follow the BuyerVoice canonical pattern: dashed reference lines show overall sample averages including the focal subgroup; significance tests compare the focal subgroup against all OTHER respondents combined. Three-tier claim discipline applies: significant findings get strong claims, non-significant but corroborated patterns get hedged language ("directionally," "suggestive"), uncorroborated non-significant patterns are not claimed at all.
8c. Coding and Reliability
Magnitude coding captures three dimensions per meaning unit: thematic code, direction (positive, negative, or neutral), and intensity (1, 2, or 3). Inter-coder reliability across the 68 thematic codes was Cohen's Kappa 0.93 on thematic codes, 0.94 on direction tags, exceeding the 0.65 threshold for substantial agreement. Codebook construction used a global pass over 484 preliminary clusters drawn from 6,592 meaning units extracted across a stratified 100-participant subsample.